| Identification | Back Directory | [Name]
MC-Alkyl-Hydrazine Modified MMAF | [CAS]
1404071-64-2 | [Synonyms]
MC-Alkyl-Hydrazine Modified MMAF
2H-1,2-Oxazine, 2-[N-[4-[2-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]hydrazinyl]-4-oxobutyl]-N-methyl-L-valyl-L-valyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoyl-(αR,βR,2S)-β-methoxy-α-methyl-2-pyrrolidinepropanoyl-L-tryptophyl]tetrahydro- | [Molecular Formula]
C59H92N10O12 | [MDL Number]
MFCD32201149 | [MOL File]
1404071-64-2.mol | [Molecular Weight]
1133.44 |
| Hazard Information | Back Directory | [Uses]
MC-Alkyl-Hydrazine Modified MMAF is a agent-linker conjugate for ADC with potent antitumor activity by using the Modified MMAF (a tubulin inhibitor), linked via the noncleavable MC-Alkyl-Hydrazine[1]. | [IC 50]
Auristatin | [References]
[1] Samantha Congreve, et al. Antibody drug conjugates (ADC) Current status and mapping of ADC:s in clinical programs. |
|
|